The Norwegian Vitamin Trial (NORVIT)
Summary
The purpose of this study is to examine whether the lowering of blood homocysteine levels by treatment with B vitamins can prevent cardiovascular disease
Timeline
- Start
- 1998-12
- Primary completion
- —
- Completion
- 2004-03
Outcome
Missed primary endpoint
paper such treatment had no significant effect on the primary end point (risk ratio, 1.08; 95 percent confidence interval, 0.93 to 1.25; P=0.31). PMID 16531614 ↗
paper Also, treatment with vitamin B6 was not associated with any significant benefit with regard to the primary end point (relative risk of the primary end point, 1.14; 95 percent confidence interval, 0.98 to 1.32; P=0.09). PMID 16531614 ↗
paper Treatment with B vitamins did not lower the risk of recurrent cardiovascular disease after acute myocardial infarction. PMID 16531614 ↗
Publications
- Results Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006 Apr 13;354(15):1578-88. doi: 10.1056/NEJMoa055227. Epub 2006 Mar 12.
- Dhar I, Lysne V, Svingen GFT, Ueland PM, Gregory JF, Bonaa KH, Nygard OK. Elevated plasma cystathionine is associated with increased risk of mortality among patients with suspected or established coronary heart disease. Am J Clin Nutr. 2019 Jun 1;109(6):1546-1554. doi: 10.1093/ajcn/nqy391.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyridoxine | Unknown | 40 mg | — |
| Subject | Vitamin B12 | Other / unclassified | 0.4 mg | — |
| Subject | folic acid | Other / unclassified | 0.8 mg | — |